146.50
price down icon4.32%   -6.61
 
loading
Zoetis Inc stock is currently priced at $146.50, with a 24-hour trading volume of 6.15M. It has seen a -4.32% decreased in the last 24 hours and a -15.30% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $152.6 pivot point. If it approaches the $149.1 support level, significant changes may occur.

Zoetis Inc Stock (ZTS) Financials Data

Zoetis Inc (ZTS) Revenue 2024

ZTS reported a revenue (TTM) of $8.54 billion for the quarter ending December 31, 2023, a +5.74% rise year-over-year.
loading

Zoetis Inc (ZTS) Net Income 2024

ZTS net income (TTM) was $2.34 billion for the quarter ending December 31, 2023, a +10.88% increase year-over-year.
loading

Zoetis Inc (ZTS) Cash Flow 2024

ZTS recorded a free cash flow (TTM) of $1.62 billion for the quarter ending December 31, 2023, a +22.25% increase year-over-year.
loading

Zoetis Inc (ZTS) Earnings per Share 2024

ZTS earnings per share (TTM) was $5.07 for the quarter ending December 31, 2023, a +12.67% growth year-over-year.
loading

Zoetis Inc Stock (ZTS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lagano Roxanne
Executive Vice President
Apr 18 '24
Sale
151.17
923
139,530
14,800
Lagano Roxanne
Executive Vice President
Mar 18 '24
Sale
173.33
923
159,984
15,723
Reed Willie M
Director
Mar 11 '24
Sale
182.68
1,370
250,265
9,994
PECK KRISTIN C
Chief Executive Officer
Feb 20 '24
Option Exercise
46.09
13,000
599,170
92,366
PECK KRISTIN C
Chief Executive Officer
Feb 20 '24
Sale
187.20
13,000
2,433,636
79,366
Lagano Roxanne
Executive Vice President
Feb 20 '24
Sale
187.30
923
172,878
16,646
Lagano Roxanne
Executive Vice President
Feb 13 '24
Sale
186.86
2,848
532,177
17,569
Lagano Roxanne
Executive Vice President
Feb 12 '24
Sale
197.74
363
71,780
20,417
Lagano Roxanne
Executive Vice President
Jan 18 '24
Sale
191.43
923
176,690
17,569
Lagano Roxanne
Executive Vice President
Dec 18 '23
Sale
198.14
923
182,883
18,492
Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
drug_manufacturers_specialty_generic TAK
$13.24
price up icon 0.61%
drug_manufacturers_specialty_generic HLN
$8.22
price up icon 1.11%
$12.86
price up icon 0.63%
$11.25
price up icon 1.17%
$132.00
price down icon 0.41%
Cap:     |  Volume (24h):